FitLife Brands Q1 2025 revenue $15.9M (-4% YoY), net income $2.0M, diluted EPS $0.20

FITLIFE BRANDS, INC.

2025-Q1 EPS reported $0.20 revenue$15,936,000

Total revenue $15.9M, down 4% YoY; net income $2.0M vs $2.2M; diluted EPS $0.20 vs $0.21.
Adjusted EBITDA $3.4M, down 6% YoY; net debt $6.0M (0.4x trailing EBITDA).
Legacy FitLife revenue up 5% YoY; MRC (Dr. Tobias) revenue down 11%; MusclePharm down 6%.
MusclePharm launched Pro Series at Vitamin Shoppe in March; MRC skin care brands declined 14%.
Company sees elevated M&A deal flow; balance sheet deleveraged with $6M cash and $12M term loans.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001437749-25-016991
form_type: 8-K
ticker: FTLF
cik: 0001374328
company_name: FITLIFE BRANDS, INC.
filed_at: 2025-05-15T23:59:59+00:00
discovered_at: 2026-05-14T18:02:48.095726+00:00
generated_at: 2026-05-21T04:43:15.494109+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001437749-25-016991
json_url: https://secwatch.observer/filing/0001437749-25-016991.json
markdown_url: https://secwatch.observer/filing/0001437749-25-016991.md
text_url: https://secwatch.observer/filing/0001437749-25-016991.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1374328/000143774925016991/0001437749-25-016991-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1374328/000143774925016991/ftlf20250514_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001437749-25-016991

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.